原发性玻璃体视网膜淋巴瘤中枢神经系统进展及生存的临床因素
这项回顾性研究纳入54例原发性玻璃体视网膜淋巴瘤患者,所有患者接受玻璃体内甲氨蝶呤注射至病灶消退,其中24例接受全身大剂量甲氨蝶呤(每两周一次,共5周期),20例完成5周期。5年中枢神经系统进展累积发生率为78.0%,总生存率为69.0%。单变量和多变量分析显示,双侧病变和流式细胞术检测到B细胞克隆性是中枢神经系统进展的危险因素,完成全身大剂量甲氨蝶呤可降低中枢神经系统进展风险并影响总生存。
要点
- 双侧病变和流式细胞术检测到B细胞克隆性是中枢神经系统进展的危险因素。
- 完成全身大剂量甲氨蝶呤可降低中枢神经系统进展风险并影响总生存。
- 5年中枢神经系统进展累积发生率为78.0%,总生存率为69.0%。
核心结论
- 本研究发现的双侧病变和流式细胞术检测到B细胞克隆性等中枢神经系统进展因素,可能有助于优化治疗分层以改善原发性玻璃体视网膜淋巴瘤患者的生存。
研究设计与样本
- 回顾性研究,纳入54例在本院诊断并治疗的原发性玻璃体视网膜淋巴瘤患者。
- 所有患者接受患眼玻璃体内甲氨蝶呤注射直至病灶消退。
- 24例患者在玻璃体内甲氨蝶呤注射后接受全身大剂量甲氨蝶呤(每两周一次,共5周期),其中20例完成5周期。
主要发现
- 5年中枢神经系统进展累积发生率为78.0%,5年总生存率为69.0%。
- 单变量和多变量分析显示,双侧病变和流式细胞术检测到B细胞克隆性是中枢神经系统进展的危险因素。
- 完成全身大剂量甲氨蝶呤可降低中枢神经系统进展风险,并被确定为影响总生存的因素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary vitreoretinal lymphoma (PVRL) is a rare subtype of malignant lymphoma with a poor prognosis because of high frequency of central nervous system (CNS) progression. Identification of factors associated with CNS progression is essential to improve the prognosis of patients with PVRL. We conducted a retrospective study of 54 patients diagnosed with PVRL and treated at our hospital to identify factors associated with CNS progression and prognosis. All patients were treated with intravitreal methotrexate (MTX) injections in the affected eyes until lesion resolution. Twenty-four patients were treated with systemic administration of high-dose MTX (systemic HD-MTX) every other week for a total of five cycles following intravitreal MTX injection. Of 24 patients, 20 completed five cycles of systemic HD-MTX. The 5-year cumulative incidence of CNS progression and overall survival (OS) rate were 78.0% and 69.0% respectively. By univariate and multivariate analyses, bilateral disease and the detection of B-cell clonality confirmed by flow cytometric analysis were risk factors associated with CNS progression. Moreover, systemic HD-MTX completion reduced the risk of CNS progression and was identified as a factor affecting OS. In this study, factors for CNS progression identified may potentially contribute to the optimized therapeutic stratification to improve the survival of patients with PVRL.
引用
- Motomura Y, Yoshifuji K, Tachibana T, et al. Clinical factors for central nervous system progression and survival in primary vitreoretinal lymphoma. Br J Haematol. 2023. PMID: 38131400. doi:10.1111/bjh.19266
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。